The Czech Republic at the Forefront of Innovation: Clinical Evaluation of a Molecular Hydrogen Device Has Begun Today
Goal: Another key step toward registering the world’s first medical device
The study is designed to deliver additional clinical data required for the subsequent registration of a medical device using molecular hydrogen, with the ambition of establishing a new standard in safe, simple, and non-invasive approaches in modern medicine.
“After so many years of research, I am extremely pleased that we have finally been able to build on our previous activities in Japan and launch a study that represents another important step toward registering the world’s first medical device based on molecular hydrogen. The potential is enormous, and we already know that this simple and non-invasive approach could ultimately help people around the world,” said Professor Shigeo Ohta.
First 9 patients enrolled, recruitment continues
As of today, the study has been launched with the first nine patients. Recruitment is ongoing, with a total target of approximately 30 participants. The same inclusion criteria previously communicated in published articles and project materials remain in place.
Eligible volunteers are those who:
-
are 50–80 years of age,
-
are in overall good health,
-
have a diagnosis of mild cognitive impairment (MCI) or mild to moderate dementia, and
-
ideally reside in Ostrava or the surrounding area, where the study is being conducted.
Participation in the study does not guarantee any health benefit and should not be considered a substitute for standard medical treatment. Interested individuals may still apply by email at: david.skoloudik@H2medical.com
“Today we officially launched the study with the first nine patients. Additional patients already have their start dates scheduled, but new applicants are still welcome. I am very pleased to be part of such a groundbreaking study here in the Czech Republic, especially in direct collaboration with Japanese scientists. It is a significant moment for our healthcare system and for international cooperation,” says Professor MUDr. David Školoudík, Ph.D.
Emphasis on responsibility, quality, and robust results
The implementation team places strong emphasis on the highest quality of study execution, patient safety, correct process setup, and the rapid acquisition of data that will enable progress toward practical clinical use.
“I am looking forward to the results. My priority is to ensure that everything is set up correctly and that we obtain results as soon as possible, allowing us to move toward real-world healthcare applications,” stated PharmDr. Milan Krajíček, Ph.D., Principal Investigator.
Significance for the Czech Republic and global impact
The launch of the clinical evaluation in Ostrava confirms that the Czech Republic is capable of generating and clinically validating innovations with global reach. The project highlights social responsibility and connects science, clinical practice, and international collaboration with the aim of delivering an approach that has the potential to become accessible and scalable beyond the country’s borders.
“It is also a positive signal for investors who are gradually joining the project. It confirms that even though we are a relatively small country, we can keep pace with global trends. Abroad, it is common for small and medium-sized investors to participate in healthcare innovations and thus become part of projects with real societal impact,” concludes David Maršálek, Founder and CEO of H2 Global Group.
More information:
www.H2Global.group
www.MolekularniVodik.cz
Source: H2 Global Group
Source article: Metro.cz - https://www.metro.cz/protext/ceska-republika-v-cele-inovaci-dnes-bylo-zahajeno-klinicke-hodnoceni-pristroje-s-molekularnim-vodike.A260119_150700_metro-protext_air